niclosamide has been researched along with Malignant Melanoma in 4 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide (NCL) is an FDA-approved anthelmintic drug and is reported to have strong anti-cancer properties against various solid and liquid tumors." | 5.91 | Niclosamide inhibits epithelial-mesenchymal transition with apoptosis induction in BRAF/ NRAS mutated metastatic melanoma cells. ( Godugu, C; Nagula, S; Pooladanda, V; Thatikonda, S; Tokala, R, 2023) |
| "Malignant melanoma is one of the most aggressive and lethal skin cancer." | 5.91 | Combination of niclosamide and quinacrine inactivates Akt/HK2/Cyclin D1 axis mediated by glucose deprivation towards the inhibition of melanoma cell proliferation. ( Ding, C; Ge, X; Jiang, J; Li, S; Li, Y; Qiao, Y; Wang, D; Wang, M; Wang, Y; Zheng, X, 2023) |
| "Melanoma is the most malignant form of skin cancer across the globe." | 5.72 | Quality by design steered development of Niclosamide loaded liposomal thermogel for Melanoma: In vitro and Ex vivo evaluation. ( Bagasariya, D; Bala Singh, S; Charankumar, K; Famta, P; Fernandes, V; Kumar Khatri, D; Shah, S; Srivastava, S, 2022) |
| "Niclosamide (NCL) is an FDA-approved anthelmintic drug and is reported to have strong anti-cancer properties against various solid and liquid tumors." | 1.91 | Niclosamide inhibits epithelial-mesenchymal transition with apoptosis induction in BRAF/ NRAS mutated metastatic melanoma cells. ( Godugu, C; Nagula, S; Pooladanda, V; Thatikonda, S; Tokala, R, 2023) |
| "Malignant melanoma is one of the most aggressive and lethal skin cancer." | 1.91 | Combination of niclosamide and quinacrine inactivates Akt/HK2/Cyclin D1 axis mediated by glucose deprivation towards the inhibition of melanoma cell proliferation. ( Ding, C; Ge, X; Jiang, J; Li, S; Li, Y; Qiao, Y; Wang, D; Wang, M; Wang, Y; Zheng, X, 2023) |
| "Melanoma is the most malignant form of skin cancer across the globe." | 1.72 | Quality by design steered development of Niclosamide loaded liposomal thermogel for Melanoma: In vitro and Ex vivo evaluation. ( Bagasariya, D; Bala Singh, S; Charankumar, K; Famta, P; Fernandes, V; Kumar Khatri, D; Shah, S; Srivastava, S, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 3 (75.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shah, S | 1 |
| Famta, P | 1 |
| Fernandes, V | 1 |
| Bagasariya, D | 1 |
| Charankumar, K | 1 |
| Kumar Khatri, D | 1 |
| Bala Singh, S | 1 |
| Srivastava, S | 1 |
| Thatikonda, S | 1 |
| Pooladanda, V | 1 |
| Tokala, R | 1 |
| Nagula, S | 1 |
| Godugu, C | 1 |
| Li, S | 1 |
| Wang, D | 1 |
| Zheng, X | 1 |
| Li, Y | 1 |
| Ding, C | 1 |
| Wang, M | 1 |
| Ge, X | 1 |
| Jiang, J | 1 |
| Qiao, Y | 1 |
| Wang, Y | 1 |
| Zhou, J | 1 |
| Jin, B | 1 |
| Jin, Y | 1 |
| Liu, Y | 1 |
| Pan, J | 1 |
4 other studies available for niclosamide and Malignant Melanoma
| Article | Year |
|---|---|
Quality by design steered development of Niclosamide loaded liposomal thermogel for Melanoma: In vitro and Ex vivo evaluation.
Topics: Administration, Cutaneous; Humans; Liposomes; Melanoma; Niclosamide; Skin Neoplasms; Tumor Microenvi | 2022 |
Niclosamide inhibits epithelial-mesenchymal transition with apoptosis induction in BRAF/ NRAS mutated metastatic melanoma cells.
Topics: Apoptosis; Cell Line, Tumor; Epithelial-Mesenchymal Transition; GTP Phosphohydrolases; Humans; Melan | 2023 |
Combination of niclosamide and quinacrine inactivates Akt/HK2/Cyclin D1 axis mediated by glucose deprivation towards the inhibition of melanoma cell proliferation.
Topics: Cell Line, Tumor; Cell Proliferation; Cyclin D1; Glucose; Humans; Melanoma; Niclosamide; Proto-Oncog | 2023 |
The antihelminthic drug niclosamide effectively inhibits the malignant phenotypes of uveal melanoma
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dise | 2017 |